BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Febvre-James M, Lecureur V, Augagneur Y, Mayati A, Fardel O. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages. Int Immunopharmacol 2018;54:354-65. [PMID: 29202299 DOI: 10.1016/j.intimp.2017.11.032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res 2020;286:198070. [PMID: 32569708 DOI: 10.1016/j.virusres.2020.198070] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 27.0] [Reference Citation Analysis]
2 Wu X, Fang J, Huang Q, Chen X, Guo Z, Tian L, Zhou E, Chen J, Mu Y, Du T. Major Vault Protein Inhibits Porcine Reproductive and Respiratory Syndrome Virus Infection in CRL2843CD163 Cell Lines and Primary Porcine Alveolar Macrophages. Viruses 2021;13:2267. [PMID: 34835073 DOI: 10.3390/v13112267] [Reference Citation Analysis]
3 Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, Fu H, Lai X, Liu L, Huang H. Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation. Front Pharmacol 2021;12:668825. [PMID: 34262450 DOI: 10.3389/fphar.2021.668825] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X 2020;2:100029. [PMID: 32421092 DOI: 10.1016/j.cytox.2020.100029] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 33.5] [Reference Citation Analysis]
5 Bruyère A, Le Vée M, Jouan E, Molez S, Nies AT, Fardel O. Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters. Xenobiotica 2021;51:467-78. [PMID: 33455503 DOI: 10.1080/00498254.2021.1875516] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu Y, Liang HM, Lv YQ, Tang SM, Cheng P. Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6. J Cell Physiol 2019;234:19702-14. [PMID: 30953364 DOI: 10.1002/jcp.28570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Goker Bagca B, Biray Avci C. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev 2020;54:51-62. [PMID: 32636055 DOI: 10.1016/j.cytogfr.2020.06.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
8 Matsunaga M, Kita T, Yamamoto R, Yamamoto N, Okano T, Omori K, Sakamoto S, Nakagawa T. Initiation of Supporting Cell Activation for Hair Cell Regeneration in the Avian Auditory Epithelium: An Explant Culture Model. Front Cell Neurosci 2020;14:583994. [PMID: 33281558 DOI: 10.3389/fncel.2020.583994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, Jouneau S, Jego P, Vernhet L, Batteux F, Fardel O, Lecureur V. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 2020;178:114103. [PMID: 32562787 DOI: 10.1016/j.bcp.2020.114103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
10 Sailliet N, Brosseau C, Robert J, Brouard S. Role of JAK inhibitors and immune cells in transplantation. Cytokine & Growth Factor Reviews 2019;47:62-73. [DOI: 10.1016/j.cytogfr.2019.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Front Oncol 2019;9:1186. [PMID: 31788449 DOI: 10.3389/fonc.2019.01186] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 20.3] [Reference Citation Analysis]
12 Khaedir Y, Kartika R. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19. J Interferon Cytokine Res 2021;41:37-43. [PMID: 33621130 DOI: 10.1089/jir.2020.0135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Salit RB, Scott BL, Stevens EA, Baker KK, Gooley TA, Deeg HJ. Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transplant 2020;55:70-6. [PMID: 30962501 DOI: 10.1038/s41409-019-0523-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
14 Marchese AM, Chiale C, Moshkani S, Robek MD. Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform. J Interferon Cytokine Res 2020;40:92-105. [PMID: 31633442 DOI: 10.1089/jir.2019.0123] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Febvre-James M, Lecureur V, Fardel O. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes. Inflamm Res 2020;69:51-62. [PMID: 31654094 DOI: 10.1007/s00011-019-01293-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Eslamloo K, Ghorbani A, Xue X, Inkpen SM, Larijani M, Rise ML. Characterization and Transcript Expression Analyses of Atlantic Cod Viperin. Front Immunol 2019;10:311. [PMID: 30894853 DOI: 10.3389/fimmu.2019.00311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
17 . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021;6:eabi9007. [PMID: 34010142 DOI: 10.1126/sciimmunol.abi9007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Memoli M, Paviglianiti A, Malard F, Battipaglia G, Brissot E, Médiavilla C, Bianchessi A, Banet A, Van de Wyngaert Z, Ledraa T, Belhocine R, Sestili S, Lapusan S, Hirsch P, Favale F, Boussaroque A, Bonnin A, Vekhoff A, Legrand O, Mohty M, Duléry R. Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. Leukemia & Lymphoma 2021;62:419-27. [DOI: 10.1080/10428194.2020.1827246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen DY, Khan N, Close BJ, Goel RK, Blum B, Tavares AH, Kenney D, Conway HL, Ewoldt JK, Chitalia VC, Crossland NA, Chen CS, Kotton DN, Baker SC, Fuchs SY, Connor JH, Douam F, Emili A, Saeed M. SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway. J Virol 2021;:JVI0086221. [PMID: 34260266 DOI: 10.1128/JVI.00862-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Alim K, Bruyère A, Lescoat A, Jouan E, Lecureur V, Le Vée M, Fardel O. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Expert Opin Drug Metab Toxicol 2021;17:259-71. [PMID: 33292029 DOI: 10.1080/17425255.2021.1862084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
21 Shah MA, Beuerlein KG, Jorizzo JL, Feldman SR. Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir? J Dermatolog Treat 2021;32:669-72. [PMID: 34493136 DOI: 10.1080/09546634.2021.1978665] [Reference Citation Analysis]